Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Study links high number of copies of chromosomal region to chemotherapeutic drug resistance

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Oral androgen receptor inhibitor improves outcomes for men with mHSPC

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Study defines biomarker in response to treatment of castration-resistant prostate cancer

Study defines biomarker in response to treatment of castration-resistant prostate cancer

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Prostate radiotherapy improves survival in men with low burden of metastatic disease

Researchers discover secret communication hotline between breast cancers and normal cells

Researchers discover secret communication hotline between breast cancers and normal cells

New combination therapy for cancer cells could soon be a reality

New combination therapy for cancer cells could soon be a reality

European Commission approves Pfizer’s first oncology biosimilar

European Commission approves Pfizer’s first oncology biosimilar

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Study reveals new protective mechanism for tumor cells in breast cancer

Study reveals new protective mechanism for tumor cells in breast cancer

Treating metastatic breast cancer with immunotherapy

Treating metastatic breast cancer with immunotherapy

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Combination treatment improves progression-free survival in patients with advanced urothelial cancer

Two new treatments may benefit patients with high risk prostate cancer, trial shows

Two new treatments may benefit patients with high risk prostate cancer, trial shows

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

New trial confirms superiority of triplet regimen over standard care in resectable esophago-gastric cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Immunotherapy found to be smarter, kinder treatment for people with head and neck cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Standard therapy plus abiraterone lowers relative risk of death in men with advanced prostate cancer

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients

Researchers use mathematical modeling to find effective chemotherapy treatments for cancer patients